Enhanced survival from CLP-induced sepsis following late administration of low doses of anti-IFNγ F(ab')2 antibody fragments

Inflammation Research

Volumn 60, Issue 10, 2011, Pages 947-953

  Marquez Velasco R ^a,e   Martinez Velazquez A X ^a   Amezcua Guerra, L M ^a   Flores Guzman F ^f   Diaz Quinonez A ^c   Masso F ^a   Paniagua Solis J ^b   Bojalil, R ^a,d  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b Laboratorios Silanes   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^e UNIVERSIDAD DEL VALLE DE MÉXICO   (Mexico)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anti interferon gamma; Cytokine; Mice; Modulation; Sepsis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN F(AB')2 FRAGMENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CECUM LIGATION; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LIGATION; LOW DRUG DOSE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PUNCTURE; REGULATORY MECHANISM; SEPSIS; SHAM PROCEDURE; SURVIVAL RATE;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; SEPSIS; TIME FACTORS;

EID: 80955165926     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-011-0355-0     Document Type: Article

References (29)

1. Bochud P, Calandra T. Science, medicine, and future: pathogenesis of sepsis: new concepts and applications for future treatment. BMJ. 2003;326:262-6. (Pubitemid 36169594)
2. Bone R, Grodzin Ch, Balk RA. Sepsis: a new hypothesis for pathogenesis of disease process. Chest. 1997;112:235-43. (Pubitemid 27343624)
3. Osuchowski MF, Welch K, Siddiqui J, Remick DG. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/ CARS continuum in sepsis and predict mortality. J Immunol. 2006;177:1967-74. (Pubitemid 44092537)
4. Remick D. Pathophysiology of sepsis. Am J Pathol. 2007;170: 1435-44. (Pubitemid 47339289)
5. van der Poll T. Immunotherapy of sepsis. Lancet Infect Dis. 2001;1:165-74. (Pubitemid 33586050)
6. Yang H, Wang H, Czura CJ, Tracey KJ. HMGB1 as a cytokine and therapeutic target. J Endotoxin Res. 2002;8:469-72.
7. Oku H, Nakazato H, Horikawa T, Tsuruta Y, Suzuki R. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol. 2002;446:167-76. (Pubitemid 34722571)
8. Kang JS, Jeon YJ, Park SK, Yang KH, Kim HM. Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1beta and prostaglandin E2 synthesis by silymarin. Biochem Pharmacol. 2004;67:175-81. (Pubitemid 37518545)
9. Yin K, Gribbin E, Wang H. Interferon-gamma inhibition attenuates lethality after cecal ligation and puncture in rats: implication of high mobility group box-1. Shock. 2005;24:396-401. (Pubitemid 41416528)
10. Márquez-Velasco R, Bojalil R, Buelna A, Flores-Guzmán F, Estevez-Ramrez J, Laguna J, Hernández AM, Daz-Quiñonez A, Paniagua-Sols JF. Anti-tumor necrosis factor a F(ab0)2 antibody fragments protect in murine polymicrobial sepsis: concentration and early intervention are fundamental to outcome. Inflamm Res. 2006;55:378-84. (Pubitemid 44825295)
11. Varma TK, Lin CY, Toliver-Kinsky TE, Sherwood ER. Endotoxin- induced gamma interferon production: contributing cell types and key regulatory factors. Clin Diagn Lab Immunol. 2002;9:530-43. (Pubitemid 34538210)
12. Kohler J, Heumann D, LeRoy D, Bailat S, Barras C, Baumgarnter JD, Glauser MP. IFN-gamma involvement in severity of gramnegative infections in mice. J Immunol. 1993;151:916-21. (Pubitemid 23215757)
13. Döcke WD, Randow F, Surbe U. Monocyte deactivation in septic patients: restoration by IFN-g treatment. Nat Med. 1997;3:678-81. (Pubitemid 27264980)
14. Andrew S, Titus J. Fragmentation of immunoglobulin G. In: Coligan J, Kruisbeek A, Margulies D, Shevach E, Strober W, editors. Current protocols in immunology. vol. 1. New York: John Wiley & Sons, Inc; 2002. 2.8.1-2.8.10.
15. López de Silanes J, Mancilla NR, Paniagua SJ. 23.03.2004. Pharmaceutical composition of F(ab0)2 antibody fragments and a process for the preparation thereof. 2004. US patent 6,709,655 B2.
16. López de Silanes J, Mancilla NR, Paniagua SJ. 31.08.2005. Composición farmacéutica de fragmentos F(ab0)2 de anticuerpos y un proceso para su preparación. 2005. Mexico patent 230257.
17. Coffey MJ, Phare SM, Peters-Golden M. Induction of inducible nitric oxide synthase by lipopolysaccharide/interferon gamma and sepsis down-regulates 5-lipoxygenase metabolism in murine alveolar macrophages. Exp Lung Res. 2004;30:615-33. (Pubitemid 39202404)
18. Ebong S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun. 1999;67:6603-10.
19. Stewart D, Fulton WB, Wilson Ch, Monitto CL, Paidas Ch, Reeves R, De Maio A. Genetic contribution to the septic response in a mouse model. Shock. 2002;18:342-7.
20. Lainée P, Efron P, Tschoeke SK, Elies L, De Winter H, Lorre K, Moldawer LL. Delayed neutralization of interferon-gamma prevents lethality in primate gram-negative bacteremic shock. Crit Care Med. 2005;33:797-805.
21. Hacke CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Van Strack Schijndel RJ, Eerenberg-Belmer AJ, Thijs LG, Aarden LA. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989;74:1704-10. (Pubitemid 19251549)
22. Damas P, Ledoux D, Nys M, Vrindts Y, Groote D, Franchimont P, Lamy M. Cytokine serum level during severe sepsis in human IL-6 as marker of sepsis. Ann Surg. 1992;215:356-62.
23. Panacek EA, Marshall JC, Alberston TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, Theo L, Van Meter L, Daum L, Lemeshow S, Hicklin G, Doig C. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab0)2 fragment afelimomab in patient with severe sepsis and elevated interleukin-6. Crit Care Med. 2004;32:2173.
24. Dinarello Ch A. Blocking IL-1 in systemic inflammation. JEM. 2005;201:1355-9.
25. Steensberg A, Fischer Ch, Keller C, Dinarello Ch A. Blocking IL-1 in systemic inflammation. JEM. 2005;201:1355-9.
26. Márquez-Velasco R, Massó F, Hernández-Pando R, Montaño LF, Springall R, Amezcua-Guerra LM, Bojalil R. LPS pretreatment by the oral route protects against sepsis induced by cecal ligation and puncture. Regulation of proinflammatory response and IgM anti-LPS antibody production as associated mechanisms. Inflamm Res. 2007;56:385-90. (Pubitemid 47443561)
27. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol. 1992;148:2724-30.
28. Remick D, Manohar P, Bolgos G, Rodriguez J, Moldawer L, Wollenberg G. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not lethality of cecal ligation and puncture. Shock. 1995;4:89-95.
29. Remick DG, Newcomb DE, Bolgos GL, Call DR. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs cecal ligation and puncture. Shock. 2000;13:110-6.